 | • レポートコード：QYR9ST01347 • 出版社/出版日：QYResearch / 2019年9月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※本調査レポートでは、世界の良性前立腺過形成（BPH）薬市場について調査・分析し、以下の構成でお届け致します。良性前立腺過形成（BPH）薬の種類別には、アルファブロッカー、ホスホジエステラーゼ5型阻害剤、5-アルファレダクターゼ阻害剤に、用途別には、男性、女性に、地域別には、北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカなどに区分してセグメント分析を行いました。 ・調査販売 ・エグゼクティブ・サマリー ・企業別良性前立腺過形成（BPH）薬売上データ ・地域別良性前立腺過形成（BPH）薬市場規模：北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカ、その他 ・種類別良性前立腺過形成（BPH）薬市場規模：アルファブロッカー、ホスホジエステラーゼ5型阻害剤、5-アルファレダクターゼ阻害剤 ・用途別良性前立腺過形成（BPH）薬市場規模：男性、女性 ・主要メーカーの企業情報：Astellas Pharma、Eli Lilly、GlaxoSmithKline、Sanofi、ADC Therapeutics、Bayer HealthCare、Bristol-Myers Squibb、Valeant Pharmaceuticals、Endo Pharmaceuticals、Foresee Pharmaceuticals ・良性前立腺過形成（BPH）薬の市場規模予測 ・バリューチェーン及び販売チャネル分析 ・市場機会・課題・リスク・影響因子分析 ... |
Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.
The global Benign Prostatic Hyperplasia (BPH) Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Benign Prostatic Hyperplasia (BPH) Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Benign Prostatic Hyperplasia (BPH) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Benign Prostatic Hyperplasia (BPH) Drugs in these regions.
This research report categorizes the global Benign Prostatic Hyperplasia (BPH) Drugs market by top players/brands, region, type and end user. This report also studies the global Benign Prostatic Hyperplasia (BPH) Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Market size by Product
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
5-Alpha-Reductase Inhibitors
Market size by End User
Men
Women
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Benign Prostatic Hyperplasia (BPH) Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Benign Prostatic Hyperplasia (BPH) Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Benign Prostatic Hyperplasia (BPH) Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Benign Prostatic Hyperplasia (BPH) Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Benign Prostatic Hyperplasia (BPH) Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Benign Prostatic Hyperplasia (BPH) Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
レポート目次Table of Contents
1 Study Coverage
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Product
1.4.2 Alpha-Blocker
1.4.3 Phosphodiesterase Type-5 Inhibitors
1.4.4 5-Alpha-Reductase Inhibitors
1.5 Market by End User
1.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by End User
1.5.2 Men
1.5.3 Women
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2014-2025
2.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2014-2025
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Growth Rate by Regions
2.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions
2.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers
3.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers
3.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers
3.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers
3.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2014-2019)
3.3 Benign Prostatic Hyperplasia (BPH) Drugs Price by Manufacturers
3.4 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution, Product Types
3.4.1 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Product
4.3 Benign Prostatic Hyperplasia (BPH) Drugs Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by End User
6 North America
6.1 North America Benign Prostatic Hyperplasia (BPH) Drugs by Countries
6.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries
6.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Benign Prostatic Hyperplasia (BPH) Drugs by Product
6.3 North America Benign Prostatic Hyperplasia (BPH) Drugs by End User
7 Europe
7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Countries
7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries
7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Product
7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs by End User
8 Asia Pacific
8.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs by Countries
8.1.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries
8.1.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs by Product
8.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs by End User
9 Central & South America
9.1 Central & South America Benign Prostatic Hyperplasia (BPH) Drugs by Countries
9.1.1 Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries
9.1.2 Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Benign Prostatic Hyperplasia (BPH) Drugs by Product
9.3 Central & South America Benign Prostatic Hyperplasia (BPH) Drugs by End User
10 Middle East and Africa
10.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs by Countries
10.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries
10.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs by Product
10.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs by End User
11 Company Profiles
11.1 Astellas Pharma
11.1.1 Astellas Pharma Company Details
11.1.2 Company Business Overview
11.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
11.1.5 Astellas Pharma Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Company Business Overview
11.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
11.2.5 Eli Lilly Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 Company Business Overview
11.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.3.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
11.3.5 GlaxoSmithKline Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Company Business Overview
11.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
11.4.5 Sanofi Recent Development
11.5 ADC Therapeutics
11.5.1 ADC Therapeutics Company Details
11.5.2 Company Business Overview
11.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.5.4 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
11.5.5 ADC Therapeutics Recent Development
11.6 Bayer HealthCare
11.6.1 Bayer HealthCare Company Details
11.6.2 Company Business Overview
11.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
11.6.5 Bayer HealthCare Recent Development
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Company Details
11.7.2 Company Business Overview
11.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
11.7.5 Bristol-Myers Squibb Recent Development
11.8 Valeant Pharmaceuticals
11.8.1 Valeant Pharmaceuticals Company Details
11.8.2 Company Business Overview
11.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
11.8.5 Valeant Pharmaceuticals Recent Development
11.9 Endo Pharmaceuticals
11.9.1 Endo Pharmaceuticals Company Details
11.9.2 Company Business Overview
11.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
11.9.5 Endo Pharmaceuticals Recent Development
11.10 Foresee Pharmaceuticals
11.10.1 Foresee Pharmaceuticals Company Details
11.10.2 Company Business Overview
11.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
11.10.5 Foresee Pharmaceuticals Recent Development
12 Future Forecast
12.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Regions
12.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Regions 2019-2025
12.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Regions 2019-2025
12.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by Product
12.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Product 2019-2025
12.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Product 2019-2025
12.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast by End User
12.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Forecast
12.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Forecast
12.6 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Forecast
12.7 Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Forecast
12.8 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Benign Prostatic Hyperplasia (BPH) Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Figure Benign Prostatic Hyperplasia (BPH) Drugs Product Picture
Table Benign Prostatic Hyperplasia (BPH) Drugs Market Segments
Table Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Covered
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Product 2019-2025 (K MT) & (Million US$)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Product 2014-2025
Figure Alpha-Blocker Product Picture
Table Major Manufacturers of Alpha-Blocker
Figure Phosphodiesterase Type-5 Inhibitors Product Picture
Table Major Manufacturers of Phosphodiesterase Type-5 Inhibitors
Figure 5-Alpha-Reductase Inhibitors Product Picture
Table Major Manufacturers of 5-Alpha-Reductase Inhibitors
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by End User 2019-2025 (K MT)
Figure Men
Figure Women
Figure Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size 2014-2025 (Million US$)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2014-2025 (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Regions 2014-2019 (K MT) & (Million US$)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Regions 2014-2019 (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions 2014-2019
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions 2014-2019
Figure 2018 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Regions 2014-2019 (Million US$)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions 2014-2019
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions 2014-2019
Figure 2018 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2014-2019) (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers (2014-2019)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers in 2018
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2014-2019) (Million USD)
Table Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2014-2019)
Figure Benign Prostatic Hyperplasia (BPH) Drugs Value Share by Manufacturers in 2018
Table Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Price (2014-2019) (USD/MT)
Table Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
Table Date of International Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product (2014-2019) (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Product (2014-2019)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Product (2014-2019)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Product in 2018
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Product (2014-2019) (Million US$)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Product (2014-2019)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Product (2014-2019)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Product in 2018
Table Benign Prostatic Hyperplasia (BPH) Drugs Price by Product 2014-2019 (USD/MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by End User (2014-2019) (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by End User (2014-2019)
Figure Global Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Share by End User (2014-2019)
Figure Global Sales Benign Prostatic Hyperplasia (BPH) Drugs Market Share by End User in 2018
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2014-2019 (K MT)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2014-2019) (K MT)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2014-2019) (Million US$)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (K MT)
Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product (2014-2019) (K MT)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Product (2014-2019)
Figure 2018 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Product
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by End User (2014-2019) (K MT)
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by End User (2014-2019)
Figure 2018 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Share by End User
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2014-2019 (K MT)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2014-2019) (K MT)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2014-2019) (Million US$)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product (2014-2019) (K MT)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Product (2014-2019)
Figure 2018 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Product
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by End User (2014-2019) (K MT)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by End User (2014-2019)
Figure 2018 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Share by End User
Figure Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2014-2019 (K MT)
Figure Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2014-2019) (K MT)
Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries
Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2014-2019) (Million US$)
Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Indonesia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Indonesia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Malaysia Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Malaysia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Philippines Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Philippines Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Thailand Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Thailand Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Vietnam Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Vietnam Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Singapore Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Singapore Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product (2014-2019) (K MT)
Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Product (2014-2019)
Figure 2018 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Product
Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by End User (2014-2019) (K MT)
Table Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by End User (2014-2019)
Figure 2018 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Share by End User
Figure Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2014-2019 (K MT)
Figure Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2014-2019) (K MT)
Table Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries
Table Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2014-2019) (Million US$)
Table Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries
Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Argentina Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product (2014-2019) (K MT)
Table Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Product (2014-2019)
Figure 2018 Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Product
Table Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by End User (2014-2019) (K MT)
Table Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by End User (2014-2019)
Figure 2018 Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Market Share by End User
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2014-2019 (K MT)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2014-2019 (Million US$)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Countries (2014-2019) (K MT)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2014-2019) (Million US$)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries
Figure GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2014-2019) (K MT)
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2014-2019) (Million US$)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Product (2014-2019) (K MT)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Product (2014-2019)
Figure 2018 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Product
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by End User (2014-2019) (K MT)
Table Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by End User (2014-2019)
Figure 2018 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Share by End User
Table Astellas Pharma Company Details
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Astellas Pharma Recent Development
Table Eli Lilly Company Details
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Eli Lilly Recent Development
Table GlaxoSmithKline Company Details
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table GlaxoSmithKline Recent Development
Table Sanofi Company Details
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Sanofi Recent Development
Table ADC Therapeutics Company Details
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table ADC Therapeutics Recent Development
Table Bayer HealthCare Company Details
Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Bayer HealthCare Recent Development
Table Bristol-Myers Squibb Company Details
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Bristol-Myers Squibb Recent Development
Table Valeant Pharmaceuticals Company Details
Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Valeant Pharmaceuticals Recent Development
Table Endo Pharmaceuticals Company Details
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Endo Pharmaceuticals Recent Development
Table Foresee Pharmaceuticals Company Details
Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2014-2019)
Table Foresee Pharmaceuticals Recent Development
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Regions 2019-2025 (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Regions 2019-2025
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Regions 2019-2025 (Million US$)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Regions 2019-2025
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Product 2019-2025 (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Product 2019-2025
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Product 2019-2025 (Million US$)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Product 2019-2025
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by End User 2019-2025 (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by End User 2019-2025
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Forecast (2019-2025) (K MT)
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Forecast (2019-2025) (K MT)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Forecast (2019-2025) (K MT)
Figure Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Forecast (2019-2025) (K MT)
Figure Central & South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Forecast (2019-2025) (K MT)
Figure Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate Forecast (2019-2025) (Million US$)
Table Benign Prostatic Hyperplasia (BPH) Drugs Value Chain
Table Benign Prostatic Hyperplasia (BPH) Drugs Customers List
Table Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
良性前立腺過形成検査の世界市場：市場規模・現状・予測 Benign prostatic hyperplasia (BPH) is a condition occurring in men when the prostate gland is enlarged. Benign prostatic hyperplasia is also termed as benign prostatic hypertrophy or benign prostatic obstruction. Prostate gland grows in primarily two phases, firstly during puberty when the size of t…- HIV薬の世界市場：インサイト・予測 HIV is a type of retrovirus that causes serious complications in humans. It generally spreads via the blood, semen, vaginal fluid, pre-ejaculate, or breast milk. The global market for HIV drugs is envisaged to surpass USD 19,000 million by 2019 owing to the recent rise in HIV patient population.One …
- 世界の良性再発性肝内胆汁うっ滞（BRIC）画像診断装置市場：専門的調査 BRIC diagnostic imaging equipment market is broadly segmented into six segments—X-ray imaging systems, CT scanners, ultrasound imaging systems, MRI systems, nuclear imaging systems, and mammography systems. The global Benign Recurrent Intrahepatic Cholestasis (BRIC) Diagnostic Imaging Equipment mar…
- 抗うつ薬の世界市場：インサイト・予測 Depression includes a variety of mental health problems characterized by the absence of a positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms. Antidepressants help maintain balance of various hormones and chemicals in the brain, which helps i…
- 認知症薬の世界市場：インサイト・予測 The global Dementia Drugs market is valued at 13900 million US$ in 2018 and will reach 26500 million US$ by the end of 2025, growing at a CAGR of 8.4% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Dementia Drugs market based on company, product ty…